Expert Opinion on Therapeutic Patents (ISSN 1354-3776 [print], 1744-7674 [electronic]) is a MEDLINE-indexed, peer-reviewed, international journal publishing review articles on recent pharmaceutical patent claims, providing expert opinion the scope for future development, in the context of the scientific literature.The Editors welcome:Reviews covering recent patent claims on compounds or applications with therapeutic potential, including biotherapeutics and small-molecule agents with specific molecular targets; and patenting trends in a particular therapeutic areaPatent Evaluations examining the aims and chemical and biological claims of individual patentsPerspectives on issues relating to intellectual propertyThe audience consists of scientists, managers and decision-makers in the pharmaceutical industry and others closely involved in R&DSample our Bioscience journals, sign in here to start your access, Latest two full volumes FREE to you for 14 days.
治疗性专利专家意见（ISSN 1354-3776 [印刷版]，1744-7674 [电子版]）是一份MEDLINE索引的、同行评审的国际期刊，发表关于近期药物专利声明的综述文章，在科学文献的背景下提供专家意见，为未来的发展提供空间。编辑们欢迎：综述涵盖近期具有治疗潜力的化合物或应用的专利声明，包括生物治疗药物和具有特定分子靶点的小分子药物;以及特定治疗领域的专利申请趋势专利评估审查单个专利的目的和化学及生物学权利要求知识产权相关问题的观点受众包括制药行业的科学家、管理人员和决策者以及其他密切参与研发的人员我们的生物科学期刊样本，请在此处登录以开始访问，最新两卷完整的期刊免费提供14天。
Carbonic anhydrase inhibition and the management of glaucoma: a literature and patent review 2013-2019
来源期刊：Expert Opinion on Therapeutic PatentsDOI：10.1080/13543776.2019.1679117
A patent review of arginine methyltransferase inhibitors (2010–2018)
来源期刊：Expert Opinion on Therapeutic PatentsDOI：10.1080/13543776.2019.1567711
MCL-1 inhibitors – where are we now (2019)?
来源期刊：Expert Opinion on Therapeutic PatentsDOI：10.1080/13543776.2019.1672661
Selective Tyk2 inhibitors as potential therapeutic agents: a patent review (2015–2018)
来源期刊：Expert Opinion on Therapeutic PatentsDOI：10.1080/13543776.2019.1567713
Agents for the prevention and treatment of age-related macular degeneration and macular edema: a literature and patent review
来源期刊：Expert Opinion on Therapeutic PatentsDOI：10.1080/13543776.2019.1671353
Peroxisome proliferator-activated receptor agonists and antagonists: a patent review (2014-present)
来源期刊：Expert Opinion on Therapeutic PatentsDOI：10.1080/13543776.2020.1703952
An updated patent review on P-glycoprotein inhibitors (2011-2018)
来源期刊：Expert Opinion on Therapeutic PatentsDOI：10.1080/13543776.2019.1618273
An updated patent review of therapeutic applications of chalcone derivatives (2014-present)
来源期刊：Expert Opinion on Therapeutic PatentsDOI：10.1080/13543776.2019.1613374
Carbonic anhydrases as disease markers
来源期刊：Expert Opinion on Therapeutic PatentsDOI：10.1080/13543776.2019.1629419
c-Met kinase inhibitors: an update patent review (2014-2017)
来源期刊：Expert Opinion on Therapeutic PatentsDOI：10.1080/13543776.2019.1552261
A patent review of histone deacetylase 6 inhibitors in neurodegenerative diseases (2014-2019)
来源期刊：Expert Opinion on Therapeutic PatentsDOI：10.1080/13543776.2019.1708901
Factor XI(a) inhibitors for thrombosis: an updated patent review (2016-present)
来源期刊：Expert Opinion on Therapeutic PatentsDOI：10.1080/13543776.2020.1705783
Cancer immunotherapy using anti-TIM3/PD-1 bispecific antibody: a patent evaluation of EP3356411A1
来源期刊：Expert Opinion on Therapeutic PatentsDOI：10.1080/13543776.2019.1637422
Small molecule and peptide-based CXCR4 modulators as therapeutic agents. A patent review for the period from 2010 to 2018
来源期刊：Expert Opinion on Therapeutic PatentsDOI：10.1080/13543776.2020.1707186
Rho-kinase inhibitors in the management of glaucoma
来源期刊：Expert Opinion on Therapeutic PatentsDOI：10.1080/13543776.2019.1670812
Drug repurposing for anticancer therapies. A lesson from proton pump inhibitors
来源期刊：Expert Opinion on Therapeutic PatentsDOI：10.1080/13543776.2020.1704733
ATP-competitive DNA gyrase and topoisomerase IV inhibitors as antibacterial agents
来源期刊：Expert Opinion on Therapeutic PatentsDOI：10.1080/13543776.2019.1575362
Novel therapies for glaucoma: a patent review (2013-2019)
来源期刊：Expert Opinion on Therapeutic PatentsDOI：10.1080/13543776.2019.1653279
An update on PTEN modulators – a patent review
来源期刊：Expert Opinion on Therapeutic PatentsDOI：10.1080/13543776.2019.1669562
Patented therapeutic approaches targeting LRP/LR for cancer treatment
来源期刊：Expert Opinion on Therapeutic PatentsDOI：10.1080/13543776.2019.1693543
Treatment of cancer with a combination of LAG-3Ig and anti-PD-1/anti-PD-L1 antibodies: a patent evaluation of US2018271940 A1
来源期刊：Expert Opinion on Therapeutic PatentsDOI：10.1080/13543776.2019.1608947
Current status of GPR40/FFAR1 modulators in medicinal chemistry (2016–2019): a patent review
来源期刊：Expert Opinion on Therapeutic PatentsDOI：10.1080/13543776.2020.1698546
Adrenergic agonists and antagonists as antiglaucoma agents: a literature and patent review (2013–2019)
来源期刊：Expert Opinion on Therapeutic PatentsDOI：10.1080/13543776.2019.1665023
Update on novel purinergic P2X3 and P2X2/3 receptor antagonists and their potential therapeutic applications
来源期刊：Expert Opinion on Therapeutic PatentsDOI：10.1080/13543776.2019.1693542
Research and development of anti-Parkinson’s drugs: an analysis from the perspective of technology flows measured by patent citations
来源期刊：Expert Opinion on Therapeutic PatentsDOI：10.1080/13543776.2019.1567712
Selective COX-2 inhibitors as anticancer agents: a patent review (2014-2018)
来源期刊：Expert Opinion on Therapeutic PatentsDOI：10.1080/13543776.2019.1623880
Prostaglandin receptor agonists as antiglaucoma agents (a patent review 2013 – 2018)
来源期刊：Expert Opinion on Therapeutic PatentsDOI：10.1080/13543776.2019.1661992
Novel urate transporter 1 (URAT1) inhibitors: a review of recent patent literature (2016–2019)
来源期刊：Expert Opinion on Therapeutic PatentsDOI：10.1080/13543776.2019.1676727
Bispecific anti-OX40/CTLA-4 antibodies for advanced solid tumors: a patent evaluation of WO2018202649
来源期刊：Expert Opinion on Therapeutic PatentsDOI：10.1080/13543776.2019.1681400
A literature review of the patent publications on venetoclax – a selective Bcl-2 inhibitor: discovering the therapeutic potential of a novel chemotherapeutic agent
来源期刊：Expert Opinion on Therapeutic PatentsDOI：10.1080/13543776.2019.1627327
Current state on tryptophan 2,3-dioxygenase inhibitors: a patent review
来源期刊：Expert Opinion on Therapeutic PatentsDOI：10.1080/13543776.2019.1556638
A patent review of BRD4 inhibitors (2013-2019)
来源期刊：Expert Opinion on Therapeutic PatentsDOI：10.1080/13543776.2020.1702645
Therapeutic modulation of retinoid X receptors – SAR and therapeutic potential of RXR ligands and recent patents
来源期刊：Expert Opinion on Therapeutic PatentsDOI：10.1080/13543776.2019.1643322
MYC modulators in cancer: a patent review
来源期刊：Expert Opinion on Therapeutic PatentsDOI：10.1080/13543776.2019.1612878
mGluR2 positive allosteric modulators: an updated patent review (2013–2018)
来源期刊：Expert Opinion on Therapeutic PatentsDOI：10.1080/13543776.2019.1637421
An update on benzofuran inhibitors: a patent review
来源期刊：Expert Opinion on Therapeutic PatentsDOI：10.1080/13543776.2019.1673727
A patent review of FGFR4 selective inhibition in cancer (2007-2018)
来源期刊：Expert Opinion on Therapeutic PatentsDOI：10.1080/13543776.2019.1624720
Cancer combinatorial immunotherapy using etigilimab and nivolumab: a patent evaluation of WO2018102536
来源期刊：Expert Opinion on Therapeutic PatentsDOI：10.1080/13543776.2020.1709445
Scientific and technological prospection on transdermal formulations and complementary therapies for the treatment of primary dysmenorrhea
来源期刊：Expert Opinion on Therapeutic PatentsDOI：10.1080/13543776.2019.1562547
Trace amine associated receptor 1 (TAAR1) modulators: a patent review (2010-present)
来源期刊：Expert Opinion on Therapeutic PatentsDOI：10.1080/13543776.2020.1708900
Cancer combinatorial immunotherapy using anti-OX40 agonist and anti-PD-L1 antagonist: a patent evaluation of US2018256711A1
来源期刊：Expert Opinion on Therapeutic PatentsDOI：10.1080/13543776.2019.1634690
PI3Kδ inhibitors for the treatment of cancer: a patent review (2015-present)
来源期刊：Expert Opinion on Therapeutic PatentsDOI：10.1080/13543776.2019.1687685
GPR17 receptor modulators and their therapeutic implications: review of recent patents
来源期刊：Expert Opinion on Therapeutic PatentsDOI：10.1080/13543776.2019.1568990
Patent landscape of molecular and cellular targeted therapies for recessive dystrophic epidermolysis bullosa
来源期刊：Expert Opinion on Therapeutic PatentsDOI：10.1080/13543776.2019.1608181
Novel method of treating macular degeneration: a patent evaluation (WO2018/107005)
来源期刊：Expert Opinion on Therapeutic PatentsDOI：10.1080/13543776.2019.1661991
Systematic review and technological prospection: ethyl ferulate, a phenylpropanoid with antioxidant and neuroprotective actions
来源期刊：Expert Opinion on Therapeutic PatentsDOI：10.1080/13543776.2019.1568410
Treatment of glaucoma and ocular hypertension using rho kinase inhibitors: patent evaluation of US2018244666 and US2018256595
来源期刊：Expert Opinion on Therapeutic PatentsDOI：10.1080/13543776.2019.1658743
Correction
来源期刊：Expert Opinion on Therapeutic PatentsDOI：10.1080/13543776.2019.1639316
Evaluation of WO2014121383 A1: a process for preparation of rufinamide and intermediates
来源期刊：Expert Opinion on Therapeutic PatentsDOI：10.1080/13543776.2019.1549230
Targeted treatment of anaerobic cancer. Patent evaluation of US2016279084 and US2017056350
来源期刊：Expert Opinion on Therapeutic PatentsDOI：10.1080/13543776.2019.1558210
